EpiPen® and EpiPen Jr® Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions.

The EpiPen® auto injector contains 2 ml of adrenaline injection 1 mg/ml in a prefilled disposable automatic injection device which is designed to deliver a single dose (0.3 ml) of 0.3 mg adrenaline when activated. After activation of the auto injector, 1.7 ml remains in the auto injector.

The Epipen was manufactured by Meridian Medical Technologies of Columbia, Maryland, for Mylan Specialty L.P., Morgantown, West Virginia (a Pfizer company). The FDA approved the product in 1987. Meridian launched the 2-Pak in 2001.

each of which provides a sterile, premeasured epinephrine dose, are commonly recommended. The EpiPen Jr contains epinephrine 0.15 mg, which is an optimal dose for patients weighing approximately 15 kg; the EpiPen contains epinephrine 0.3 mg, which is optimal for patients weighing approximately 30 kg or more.

Children 7.5-20kg (aged around one to five years): EpiPen® Jr (150 microgram) or.

The 3 currently available 0.15-mg pediatric epinephrine auto-injectors (EpiPen Jr, Adrenaclick 0.15 mg, and Auvi-Q 0.15 mg) are approved by the US Food and Drug Administration (FDA) for children weighing 15 to 30 kg. Sometimes, these devices are used off-label for patients who weigh less than 15 kg.

EPIPEN® and EPIPEN JR® Auto-Injectors are used to treat life-threatening, allergic emergencies in people who are at risk for or have a history of serious allergic emergencies. EPIPEN and EPIPEN JR are for immediate administration by you or your caregiver. They do not take the place of emergency medical care.

The EpiPen® Auto-Injector (0.3 mg) is generally intended for patients who weigh 66 pounds or more (30 kilograms or more). The EpiPen® Jr Auto-Injector (0.15 mg) is generally intended for patients who weigh approximately 33 to 66 pounds (15 to 30 kilograms).

Meridian, a subsidiary of Pfizer that manufactures EpiPen® 0.3 mg and EpiPen Jr® 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, continues to experience manufacturing constraints affecting supply.

Epinephrine auto-injectors come in packages of two for a reason. It's estimated 15-30 percent of anaphylaxis episodes will require more than one auto-injector to stop symptoms. This is why they should remain stored together at all times.

EpiPen and EpiPen Jr. are automatic injection devices used to treat life- threatening allergic emergencies. EpiPen Jr. is for children and EpiPen is for adults.

The 3 currently available 0.15-mg pediatric epinephrine auto-injectors (EpiPen Jr, Adrenaclick 0.15 mg, and Auvi-Q 0.15 mg) are approved by the US Food and Drug Administration (FDA) for children weighing 15 to 30 kg. Sometimes, these devices are used off-label for patients who weigh less than 15 kg.